Acceptance code: HPR13

Regional Inequity in 4CMenB Vaccination Rates in Austria & **Correlation with Unemployment:** A Retrospective Ecological Study

4CMenB vaccination uptake rate in Austria (\mathbf{X}) was negatively correlated with unemployment





SCAN ME

Georgios Nikitas¹, Gerrit Uhl², Andrew G. Allmon³, Kieran Brooks⁴, Jennifer Gaultney⁴, Alen Marijam¹

¹GSK, Wavre, Belgium, ²GSK, Vienna, Austria, ³GSK, Durham, North Carolina, USA, ⁴IQVIA, London, United Kingdom







To investigate four-component MenB (4CMenB) vaccination rate per births and its association with unemployment

Methods

- In this retrospective, ecological correlation study, 4CMenB vaccine uptake and unemployment data were obtained (Figure 1)
- 4CMenB vaccination rate was estimated as total doses distributed, divided by doses required for newborns in the catchment population
- Correlation between 4CMenB vaccination rates and unemployment

Figure 1: Schematic of databases used





Vaccination rates

- Seasonal fluctuations in the number of 4CMenB vaccine units sold can be observed across Austrian federal states (Figure 2)
- Base case (2022 births) Austrian 4CMenB vaccination rate was 18.7% for a small proportion of the national population
- Highest vaccination rates were observed in Burgenland and Niederösterreich, while the lowest were observed in Oberösterreich and Steiermark (Figure 3)

Correlation between vaccination uptake rates and unemployment rates

- Base case analysis at district and municipality levels showed that unemployment rates correlated negatively and significantly with 4CMenB vaccination uptake rates (r=-0.43; p<0.001 for both district and municipality levels)
- This correlation remained significant when excluding Voralberg, Salzburg and Burgenland as regions with partial reimbursement, at both district and municipality levels (Figure 4)


Figure 3: 4CMenB vaccination coverage rates across Austrian federal states in 2022

	4CMenB vaccination coverage rates (%)	Lower Austria Vie Upper Austria	
Overall	18.7	Opper Austria	
Federal States		Vorarlberg Salzburg	
Burgenland	48.1		
Lower Austria	32.4		
Vorarlberg	24.6		
Tyrol	23.9	Tyrol Burgen	
Salzburg	17.8	Styria	
Vienna	8.6	4CMenB vaccination coverage rates (%)	
Upper Austria	6.4		
Styria	3.6	<10 10-24 25-49 50-100	

4CMenB vaccine uptake from January 2022–February 2023. Carinthia was excluded from analysis as an outlier; Carinthia vaccination rates were inflated by one pharmacy, with similar observations made for other vaccines

• Sensitivity analyses showed similar results across Austrian districts and municipalities when the correlation analysis was repeated for 2019 (r=-0.47, p<0.01 and r=-0.28, p<0.01, respectively) and 2021 (r=-0.36, p<0.01 and r=-0.27, p<0.01, respectively)

Figure 4: Correlation between 4CMenB vaccination uptake rates and unemployment rates (excluding regions with partial reimbursement) across Austrian districts (A) and municipalities (B) in 2022




Correlation measured using Spearman's coefficient; Two-tailed p-value used. 4CMenB vaccination uptake from January 2022-February 2023; unemployment rate in 2022



• Despite a recent decline in invasive meningococcal disease (IMD)

Conclusions



Vienna

Burgenland

This study was limited by database coverage and uncertainties in vaccination rates, as not all Austrian pharmacies were included and it was assumed that vaccination rates represent the

- cases, meningococcal serogroup B (MenB) remains the most reported IMD serogroup in Europe¹
- The 4CMenB vaccine provides protection against MenB²
- MenB vaccination is recommended in Austria for those aged 2 months-<25 years, but is not included in the National Immunisation Program³

• As it is a non-funded vaccine, access to 4CMenB vaccine may vary by region and socioeconomic status





Inclusion of the 4CMenB vaccine into Austria's National Immunisation Program could reduce the inequity seen in vaccination rates

Despite this, the analysis showed that 4CMenB vaccination uptake rate in Austria was

negatively correlated with unemployment, a socioeconomic factor with disparity across

Abbreviations

4CMenB, four-component MenB; IMD, invasive meningococcal disease; MenB, meningococcal serogroup B

References

- 1. European Centre for Disease Prevention and Control. Invasive meningococcal disease: Annual Epidemiological Report for 2021. Available at: www.ecdc.europa.eu/sites/default/files/documents/MEN%20AER%202021.pdf (Accessed: September 2024) 2. European Medicines Agency. Bexsero. Available at: www.ema.europa.eu/en/documents/overview/bexsero-epar-summary
 - public_en.pdf (Accessed: September 2024)
 - 3. Bundesministeriums für Soziales, Gesundheit, Pflege und Konsumentenschutz. Impfplan Österreich 2023/2024. Available at: https://www.sozialministerium.at/Themen/Gesundheit/Impfen/Impfplan-%C3%96sterreich.html (Accessed: September 2024) 4. Organisation for Economic Co-operation and Development. Regions and Cities at a Glance 2020. Available at: https://www. oecd.org/en/publications/oecd-regions-and-cities-at-a-glance-2020_959d5ba0-en.html (Accessed: October 2024)

Disclosures

different regions in Austria⁴

GN: employee of, holds financial equities in and has received grants/contracts from GSK; **GU:** employee of GSK; **AGA** and **AM**: employees of and hold financial equities in GSK; **KB** and **JG**: employees of IQVIA which was paid by GSK to conduct this study

Acknowledgements

The authors thank Hannah Russell, Costello Medical, UK for medical writing assistance and publication coordination, and the Costello Medical Creative team for design support, funded by GSK

Funding

This study (VEO-000792), and all costs associated with publication development, were funded by GSK



ISPOR Europe 2024 | 17–20 November 2024 | Barcelona, Spain

Presenting author: Gerrit Uhl, gerrit.v.uhl@gsk.com